Skip to main content

Advertisement

SpringerLink
Log in

The involvement of myocyte enhancer factor 2D in regulating tumor biology of cardiac myxoma

  • Original Article
  • Published:
Tumor Biology

Abstract

The pro-survival transcription factor myocyte enhancer factor 2D (MEF2D) is identified to exhibit pro-tumor effects based on clinical and experimental studies. However, the detailed mechanisms underlying IGF-1-MEF2D pathway-induced tumor biology in cardiac myxoma (CM) was not clear. Here, we investigated the role of MEF2D in CM tissues and cells using RT-PCR, western blot, gene silencing, et al. Our findings revealed MEF2D was significantly increased in CM tissues compared with adjacent normal tissues and closely related to tumor size. In vitro assay demonstrated that IGF-1 enhanced CM cell proliferation in a time-dependent fashion. However, knockdown of MEF2D reversed the IGF-1-induced proliferative effects on CM cells in a time-dependent fashion and further resulted in cell cycle arrest. Based on the molecular level, IGF-1 enhanced the expression of epidermal growth factor receptor (EGFR) and matrix metalloprotein 9 (MMP9) in CM cells, whereas knockdown of MEF2D was able to reduce the expression of EGFR and MMP9 compared with vector control. Furthermore, we found knockdown of MEF2D directly affected G1/S transition in cultured CM cells. In conclusion, MEF2D regulates IGF-1-induced proliferation and apoptosis in CM development, indicating IGF-1-MEF2D pathway may be a useful target for treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Lim CH, Tan NC, Chia BL, Tan L. The authors indicated no potential conflicts of interest. Atrial myxoma. Singapore Med J. 1977;18:68–75.

    CAS  PubMed  Google Scholar 

  2. Goswami KC, Shrivastava S, Bahl VK, Saxena A, Manchanda SC, Wasir HS. Cardiac myxomas: clinical and echocardiographic profile. Int J Cardiol. 1998;63:251–9.

    Article  CAS  PubMed  Google Scholar 

  3. Ouattara A, Boccara G, Chiche L, Coriat P. Intraoperative diagnosis of an unsuspected left atrial myxoma by transesophageal echocardiography. Anesth Analg. 2002;94:1458–9.

    PubMed  Google Scholar 

  4. Gonzalez-Juanatey C, Regueiro-Abel M, Lopez-Agreda H, Peña-Martínez F, Gonzalez-Gay MA. Giant left atrial myxoma mimicking severe mitral valve stenosis. Int J Cardiol. 2008;127:e110–2.

    Article  PubMed  Google Scholar 

  5. Rahmanian PB, Castillo JG, Sanz J, Adams DH, Filsoufi F. Cardiac myxoma: preoperative diagnosis using a multimodal imaging approach and surgical outcome in a large contemporary series. Interact Cardiovasc Thorac Surg. 2007;6:479–83.

    Article  PubMed  Google Scholar 

  6. Fang C, Shen Y, Qi P, et al. Astrocyte-elevated gene-1 mediates insulin-like growth factor 1-induced the progression of cardiac myxoma. Tumour Biol. 2015.

  7. Bai XL, Zhang Q, Ye LY, et al. Myocyte enhancer factor 2C regulation of hepatocellular carcinoma via vascular endothelial growth factor and Wnt/beta-catenin signaling. Oncogene. 2015;34(31):4089–97.

    Article  CAS  PubMed  Google Scholar 

  8. Ma L, Liu J, Liu L, et al. Overexpression of the transcription factor MEF2D in hepatocellular carcinoma sustains malignant character by suppressing G2-M transition genes. Cancer Res. 2014;74(5):1452–62.

    Article  CAS  PubMed  Google Scholar 

  9. Yu W, Huang C, Wang Q, et al. MEF2 transcription factors promotes EMT and invasiveness of hepatocellular carcinoma through TGF-β1 autoregulation circuitry. Tumour Biol. 2014;35(11):10943–51.

    Article  CAS  PubMed  Google Scholar 

  10. Zhao X, Liu M, Li D. Oleanolic acid suppresses the proliferation of lung carcinoma cells by miR-122/cyclin G1/MEF2D axis. Mol Cell Biochem. 2015;400(1–2):1–7.

    Article  CAS  PubMed  Google Scholar 

  11. Cante-Barrett K, Pieters R, Meijerink JP. Myocyte enhancer factor 2C in hematopoiesis and leukemia. Oncogene. 2014;33(4):403–10.

    Article  CAS  PubMed  Google Scholar 

  12. Yu H, Sun H, Bai Y, et al. MEF2D overexpression contributes to the progression of osteosarcoma. Gene. 2015;563(2):130–5.

    Article  CAS  PubMed  Google Scholar 

  13. Lopez-Chavez A, Carter CA, Giaccone G. The role of KRAS mutations in resistance to EGFR inhibition in the treatment of cancer. Curr Opin Investig Drugs. 2009;10(12):1305–14.

    CAS  PubMed  Google Scholar 

  14. Dai C, Lv S, Shi R, et al. Nuclear protein C23 on the cell surface plays an important role in activation of CXCR4 signaling in glioblastoma. Mol Neurobiol. 2015;52(3):1521–6.

    Article  CAS  PubMed  Google Scholar 

  15. Yang X, Lv S, Liu Y, et al. The clinical utility of matrix metalloproteinase 9 in evaluating pathological grade and prognosis of glioma patients: a meta-analysis. Mol Neurobiol. 2015;52(1):38–44.

    Article  CAS  PubMed  Google Scholar 

  16. Han G, Wu D, Yang Y, et al. CrkL meditates CCL20/CCR6-induced EMT in gastric cancer. Cytokine. 2015;76(2):163–9.

    Article  CAS  PubMed  Google Scholar 

  17. Li J, Li H, Liu J, et al. The clinical implications of human telomerase reverse transcriptase expression in grade and prognosis of gliomas: a systematic review and meta-analysis. Mol Neurobiol. 2015.

  18. Yang X, Lv S, Zhou X, et al. The clinical implications of transforming growth factor beta in pathological grade and prognosis of glioma patients: a meta-analysis. Mol Neurobiol. 2015;52(1):270–6.

    Article  CAS  PubMed  Google Scholar 

  19. Warburton D, Shi W, Xu B. TGF-β-Smad3 signaling in emphysema and pulmonary fibrosis: an epigenetic aberration of normal development? Am J Physiol Lung Cell Mol Physiol. 2013;304(2):L83–5.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We greatly thank other members of our lab for valuable suggestions and writing.

Author information

Authors and Affiliations

  1. Department of Cardiac Surgery, Qingdao Branch, Qilu Hospital of Shandong University, No. 758 Hefei Road, Shibei District, Qingdao, Shandong, China

    Yufeng Huo, Fen Zhao & Yinghai Du

  2. Department of Anesthesia, ZhangQiu People’s Hospital, No. 1920, Huiquan Road, Zhangqiu, Shandong, China

    Qingjun Zhao

  3. Department of Cardiothoracic Surgery, JiMo People’s Hospital, Qingdao, Shandong, China

    Cheng Wang

  4. Department of Cardiac Surgery, Qilu Hospital of Shandong University, No. 107 West Wenhua Road, 250012, Jinan, China

    Wenyu Sun

Authors
  1. Yufeng Huo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qingjun Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cheng Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fen Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yinghai Du
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wenyu Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wenyu Sun.

Ethics declarations

Conflicts of interest

None

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huo, Y., Zhao, Q., Wang, C. et al. The involvement of myocyte enhancer factor 2D in regulating tumor biology of cardiac myxoma. Tumor Biol. 37, 5405–5411 (2016). https://doi.org/10.1007/s13277-015-4386-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-4386-y

Keywords

Search

Navigation